Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics director Kevin Robert Lind was granted a stock option on 10/01/2025 to buy 40,200 shares of common stock at an exercise price of $12.96. The option becomes exercisable in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the director's continued service. The option expires on 10/01/2035 and the reporting Form 4 was filed on 10/02/2025 by power of attorney. The grant is reported as a direct holding and shows 40,200 shares underlying the derivative security following the transaction.
Avalo Therapeutics, Inc. (AVTX) director Kevin Robert Lind filed an initial Form 3 reporting that he does not beneficially own any securities of the issuer. The Form 3 lists the qualifying event date as 10/01/2025 and is signed by Donald R. Reynolds by power of attorney on 10/02/2025. The filing gives the reporter's address as 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.
Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.
Avalo Therapeutics, Inc. reported the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, including senior roles at Abzena and Longboard Pharmaceuticals, where he led significant M&A and licensing activity.
Under an employment agreement dated September 29, 2025, Boyd will receive a base salary of $465,000 and a discretionary annual bonus targeted at up to 40% of base salary, payable in cash or, if mutually agreed, immediately vested equity. As an inducement, he will be granted a stock option for 275,000 shares of Avalo common stock on October 1, 2025, with an exercise price equal to the Nasdaq closing price on the grant date and vesting over four years.
If Avalo terminates Boyd without Cause or he resigns for Good Reason, severance protections include continued salary for nine months (extended to 12 months if termination occurs within six months after a Change in Control), a prorated or enhanced bonus depending on timing, full vesting of outstanding options with six months to exercise, and up to 12 months of COBRA premium payments, all conditioned on a release of claims and compliance with confidentiality, non-disparagement, invention assignment, non-competition, and non-solicitation covenants.
Avalo Therapeutics, Inc. reported changes to its board of directors. The company’s board appointed Kevin Lind as a director effective October 1, 2025, and he will also join the Audit Committee, serving until the 2026 annual meeting or until a successor is elected and qualified.
In line with Avalo’s Amended and Restated Non-Employee Director Compensation Plan, Mr. Lind will receive a non-qualified stock option to purchase 40,200 shares of common stock on October 1, 2025, vesting in three equal annual installments, with an exercise price equal to that day’s Nasdaq Capital Market closing price.
June Almenoff, M.D., Ph.D. resigned as a director, effective October 1, 2025, to pursue new opportunities; her resignation, including from the Audit Committee, is stated as not related to the company’s operations, policies, or practices. Avalo is accelerating vesting of her outstanding equity awards as of October 1, 2025, and extending the expiration dates of her outstanding stock options to September 30, 2026.
Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.
Avalo Therapeutics (AVTX) disclosed that OrbiMed Advisors LLC beneficially holds 967,000 shares of common stock, representing 8.9% of the class, with shared voting and dispositive power over those shares. OrbiMed Capital GP IX LLC separately reports beneficial ownership of 644,667 shares, or 6.0% of the class, also with shared voting and dispositive power. The filing states these holdings are exercised on behalf of other persons and that the reported shares were not acquired to change or influence control of the issuer. Key executives on the management committee are identified as exercising voting power.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
